It will grow to $7.18 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- Save ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with ...

Myriad Genetics has a 12 month low of $8.53 and a 12 month high of $29.30. Myriad Genetics (NASDAQ:MYGN – Get Free Report) last released its quarterly earnings data on Tuesday, February 25th.

Myriad Genetics, Inc. has a 12 month low of $8.70 and a 12 month high of $29.30. The stock’s 50 day moving average price is $11.76 and its 200 day moving average price is $16.50.

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by.

Myriad Genetics earned $4 million from GeneSight testing via UnitedHealthcare in 2024. Myriad reaffirms 2025 EPS guidance of $0.07-$0.11 vs. consensus of $0.06. From tariffs to inflation, macro ...

Myriad Genetics is down 13% since the beginning of the year, and at $11.74 per share, it is trading 59% below its 52-week high of $28.60 from September 2024. Investors who bought $1,000 worth of ...

Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing.

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics posted its Q3 numbers on November 7th. The company delivered a non-GAAP profit of six cents a share, four cents a share above the consensus analyst firm estimate.

Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 11.15%.